Date: 2014-01-19
Type of information: Licensing agreement
Compound: adeno-associated viral (AAV) vector discovery and optimization technology for gene delivery to the central nervous system and liver.
Company: uniQure (The Netherlands) 4D Molecular Therapeutics (USA - CA)
Therapeutic area: CNS diseases - Liver diseases - Hepatic diseases
Type agreement: licensing collaboration
Action mechanism: gene therapy
Disease:
Details: * On January 19, 2014, uniQure., a leader in human gene therapy, and 4D Molecular Therapeutics LLC, a pioneer in next-generation gene delivery technologies, announced a broad collaboration and license agreement under which uniQure will gain exclusive access to 4D’s adeno-associated viral (AAV) vector discovery and optimization technology for gene delivery to the central nervous system and liver.
Financial terms: No financial details were disclosed.
Latest news:
